142 related articles for article (PubMed ID: 22056212)
1. Outcome assessment of patients with metastatic renal cell carcinoma under systemic therapy using artificial neural networks.
Buchner A; Kendlbacher M; Nuhn P; Tüllmann C; Haseke N; Stief CG; Staehler M
Clin Genitourin Cancer; 2012 Mar; 10(1):37-42. PubMed ID: 22056212
[TBL] [Abstract][Full Text] [Related]
2. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials.
Leibovich BC; Han KR; Bui MH; Pantuck AJ; Dorey FJ; Figlin RA; Belldegrun A
Cancer; 2003 Dec; 98(12):2566-75. PubMed ID: 14669275
[TBL] [Abstract][Full Text] [Related]
3. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
[TBL] [Abstract][Full Text] [Related]
4. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy.
Naitoh J; Kaplan A; Dorey F; Figlin R; Belldegrun A
J Urol; 1999 Jul; 162(1):46-50. PubMed ID: 10379737
[TBL] [Abstract][Full Text] [Related]
5. Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term followup.
Haferkamp A; Bastian PJ; Jakobi H; Pritsch M; Pfitzenmaier J; Albers P; Hallscheidt P; Müller SC; Hohenfellner M
J Urol; 2007 May; 177(5):1703-8. PubMed ID: 17437789
[TBL] [Abstract][Full Text] [Related]
6. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy.
Pantuck AJ; Zisman A; Dorey F; Chao DH; Han KR; Said J; Gitlitz B; Belldegrun AS; Figlin RA
Cancer; 2003 Jun; 97(12):2995-3002. PubMed ID: 12784334
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors for renal cell carcinoma with tumor thrombus extension.
Klatte T; Pantuck AJ; Riggs SB; Kleid MD; Shuch B; Zomorodian N; Kabbinavar FF; Belldegrun AS
J Urol; 2007 Oct; 178(4 Pt 1):1189-95; discussion 1195. PubMed ID: 17698087
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.
Figlin R; Gitlitz B; Franklin J; Dorey F; Moldawer N; Rausch J; deKernion J; Belldegrun A
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S92-7. PubMed ID: 9457402
[TBL] [Abstract][Full Text] [Related]
10. Integration of surgery and systemic therapy for renal cell carcinoma.
Kenney PA; Wood CG
Urol Clin North Am; 2012 May; 39(2):211-31, vii. PubMed ID: 22487764
[TBL] [Abstract][Full Text] [Related]
11. Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma.
Kwak C; Park YH; Jeong CW; Jeong H; Lee SE; Moon KC; Ku JH
J Surg Oncol; 2007 Mar; 95(4):317-23. PubMed ID: 17066434
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941.
Escudier B; Choueiri TK; Oudard S; Szczylik C; Négrier S; Ravaud A; Chevreau C; Venner P; Champagne P; Croteau D; Dupont E; Hariton C; Bukowski RM
J Urol; 2007 Nov; 178(5):1901-5. PubMed ID: 17868728
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of renicapsular involvement in Stages I and II renal cell carcinoma from the morphological and prognostic point of view.
May M; Brookman-Amissah S; Roigas J; Gilfrich CP; Pflanz S; Hoschke B; Gunia S
Urol Oncol; 2010; 28(3):274-9. PubMed ID: 18805709
[TBL] [Abstract][Full Text] [Related]
14. No role of adjuvant systemic therapy after complete metastasectomy in metastatic renal cell carcinoma?
Kwak C; Park YH; Jeong CW; Lee SE; Ku JH
Urol Oncol; 2007; 25(4):310-6. PubMed ID: 17628297
[TBL] [Abstract][Full Text] [Related]
15. Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population.
Neuzillet Y; Tillou X; Mathieu R; Long JA; Gigante M; Paparel P; Poissonnier L; Baumert H; Escudier B; Lang H; Rioux-Leclercq N; Bigot P; Bernhard JC; Albiges L; Bastien L; Petit J; Saint F; Bruyere F; Boutin JM; Brichart N; Karam G; Branchereau J; Ferriere JM; Wallerand H; Barbet S; Elkentaoui H; Hubert J; Feuillu B; Theveniaud PE; Villers A; Zini L; Descazeaux A; Roupret M; Barrou B; Fehri K; Lebret T; Tostain J; Terrier JE; Terrier N; Martin L; Dugardin F; Galliot I; Staerman F; Azemar MD; Irani J; Tisserand B; Timsit MO; Sallusto F; Rischmann P; Guy L; Valeri A; Deruelle C; Azzouzi AR; Chautard D; Mejean A; Salomon L; Rigaud J; Pfister C; Soulié M; Kleinclauss F; Badet L; Patard JJ; ;
Eur Urol; 2011 Aug; 60(2):366-73. PubMed ID: 21377780
[TBL] [Abstract][Full Text] [Related]
16. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.
Leibovich BC; Cheville JC; Lohse CM; Zincke H; Frank I; Kwon ED; Merchan JR; Blute ML
J Urol; 2005 Nov; 174(5):1759-63; discussion 1763. PubMed ID: 16217278
[TBL] [Abstract][Full Text] [Related]
17. The influence of pNx/pN0 grouping in a multivariate setting for outcome modeling in patients with clear cell renal cell carcinoma.
Ward JF; Blute ML; Cheville JC; Lohse CM; Weaver AL; Zincke H
J Urol; 2002 Jul; 168(1):56-60. PubMed ID: 12050492
[TBL] [Abstract][Full Text] [Related]
18. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies.
Belldegrun AS; Klatte T; Shuch B; LaRochelle JC; Miller DC; Said JW; Riggs SB; Zomorodian N; Kabbinavar FF; Dekernion JB; Pantuck AJ
Cancer; 2008 Nov; 113(9):2457-63. PubMed ID: 18823034
[TBL] [Abstract][Full Text] [Related]
19. Metastatic potential of a renal mass according to original tumour size at presentation.
Umbreit EC; Shimko MS; Childs MA; Lohse CM; Cheville JC; Leibovich BC; Blute ML; Thompson RH
BJU Int; 2012 Jan; 109(2):190-4; discussion 194. PubMed ID: 21557795
[TBL] [Abstract][Full Text] [Related]
20. Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma.
Belldegrun A; Shvarts O; Figlin RA
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S88-92. PubMed ID: 10685666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
